Tislelizumab trials for Lung cancer

All Tislelizumab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Tislelizumab for Lung cancer

• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
  NCT07502300 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of SKB518 in Patients With Lung Cancer
  NCT07019675 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
  NCT07652736 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
  NCT06749886 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
  NCT06745908 · Phase: Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 36 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
  NCT06868732 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
  NCT07609121 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• IN10018 Combination Therapy in Treatment-naïve ES-SCLC
  NCT06030258 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
  NCT06416410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
  NCT05886439 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
  NCT07528274 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
  NCT07264647 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
  NCT06659042 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
  NCT07468071 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 20 locations
• Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
  NCT06598527 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
  NCT05468242 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
  NCT07330037 · Phase: Phase 2 · Ages: 17 Years to 75 Years · Sex: All (male and female) · 1 location
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
  NCT06536868 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations
• tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
  NCT06332274 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Tislelizumab for Lung cancer?

21 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.